ALT241108C4000
- 0.00
- 0.000.00%
Altimmune Newsroom
Altimmune, FDA Agree on Efficacy Measures for Phase 3 Trial of Pemvidutide
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting
Express News | Altimmune Inc - Phase 3 Program to Enroll Approximately 5,000 Subjects
Express News | Altimmune Announces Successful Completion of End-of-Phase 2 Meeting With FDA for Pemvidutide in the Treatment of Obesity
Earnings Preview: Altimmune to Report Financial Results on November 12
Altimmune to Participate at Two Upcoming Investor Conferences
Calendar of U.S. Earnings Expected in the Week Ahead
Express News | Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
State Street Corp's Strategic Reduction in Altimmune Inc Holdings
Altimmune, Inc. (ALT): A Bull Case Theory
Millennium Management LLC Increases Stake in Altimmune Inc
Altimmune Call Volume Above Normal and Directionally Bullish
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated With Pemvidutide at The Liver Meeting 2024
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)
Obesity Drugs Seen Costing Medicare $35 Billion Through 2034
Piper Sandler Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report